Device developer Iconovo AB has announced the appointment of Mikael Ekström as its new VP, Development effective September 1, 2018. Ekström held various positions at AstraZeneca over a period of almost 30 years, most recently as Senior Director Inhalation Product Development. Iconovo said that Ekström's hire "is an important reinforcement of Iconovo's organization … [Read more...] about Iconovo appoints Mikael Ekström as VP of Development
People
Rick Batycky to leave Acorda ahead of FDA decision on Inbrija
Acorda Therapeutics has announced that Chief Technology Officer Rick Batycky is leaving the company as of August 20, 2018 to head up a new private biotech firm. Batycky co-founded Civitas Therapeutics, which was acquired by Acorda in 2014, along with its CVT-301 levodopa DPI, (now known as Inbrija) and the ARCUS dry powder inhalation platform. The company filed … [Read more...] about Rick Batycky to leave Acorda ahead of FDA decision on Inbrija
Proveris hires John Masciola as VP of Product Development
Proveris Scientific Corporation has announced the appointment of John Masciola as VP of Product Development. Masciola was most recently Engineering Manager at Parker Precision Fluidics, and his experience in the life sciences industry includes positions as Director of Instrument Engineering and Director of R&D at Perkin Elmer and VP of Engineering at Zymark/Caliper … [Read more...] about Proveris hires John Masciola as VP of Product Development
Cohero Health announces new management hires
Cohero Health has announced 5 new hires "to scale for growth and drive commercial sales of its BreatheSmart platform." In 2016, Cohero and H&T Presspart announced that they had partnered on development of an electronic inhaler called the eMDI. The new hires are: Amber Thompson, Chief Client Officer; Sergio Carbone, Chief Information and Technology Officer; Yury … [Read more...] about Cohero Health announces new management hires
Savara acquires rights to inhaled antibiotic, appoints new strategic advisor, and provides update on Molgradex development
Savara has acquired rights to an amikacin/fosfomycin inhalation solution that was being developed by Cardeas Pharma for the treatment of ventilator associated pneumonia and has appointed former Cardeas Pharma CEO A. Bruce Montgomery as a strategic advisor, the company said. The company also announced a public offering of common stock, with shares priced at $11.50 … [Read more...] about Savara acquires rights to inhaled antibiotic, appoints new strategic advisor, and provides update on Molgradex development
Impel NeuroPharma names Lynn Gold Senior VP of Regulatory Affairs
Intranasal drug developer Impel NeuroPharma has hired Lynn C. Gold as Senior VP of Regulatory Affairs, the company said. Gold was most recently VP of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services and had previously served as VP of Research and Process Development at Sonus Pharmaceuticals. In 2017, Impel announced that it had signed service … [Read more...] about Impel NeuroPharma names Lynn Gold Senior VP of Regulatory Affairs
Per Bäckman joins Emmace Consulting
Former Mylan Senior Director of Inhalation Biopharmaceutics Per Bäckman has joined Emmace Consulting as Senior Inhalation Consultant, the company has announced. Bäckman also previously held various positions at AstraZeneca, including as Principal Scientist in Inhalation Biopharmaceutics, and at Novo Nordisk. Emmace Consulting CEO Mårten Svensson said, "Per Bäckman … [Read more...] about Per Bäckman joins Emmace Consulting
Galecto Biotech names Richard Marshall as Chief Medical Officer
Galecto Biotech, which is developing an inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), has hired former GSK VP and Head of the Fibrosis & Lung Injury Discovery Performance Unit Richard Marshall as its Chief Medical Officer, the company said. Marshall held a number of positions in respiratory drug development at GSK over 15 … [Read more...] about Galecto Biotech names Richard Marshall as Chief Medical Officer
Liquidia Technologies appoints Jeri Thomas Senior VP, Commercial
Liquidia Technologies has named Jeri Thomas as its new Senior VP Commercial, responsible initially for commercial plans for the company's LIQ861 treprostinil DPI, which is currently in Phase 3 development for the treatment of pulmonary arterial hypertension (PAH). According to Liquidia, Thomas was most recently Senior VP, Strategic Group Planning at healthcare … [Read more...] about Liquidia Technologies appoints Jeri Thomas Senior VP, Commercial
TFF Pharmaceuticals appoints Glen Mattes as CEO
TFF Pharmaceuticals, which recently announced that it had raised $14 million for the development of DPI formulations, has named former Arno Therapeutics CEO Glenn Mattes as its new Chief Executive Officer. Mattes's career includes management and board positions with a number of pharmaceutical companies, including Johnson & Johnson subsidiaries Tibotec Therapeutics and … [Read more...] about TFF Pharmaceuticals appoints Glen Mattes as CEO